Press Releases

Avacta Group plc , the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc (AIM: SKIN) (“Integumen”) to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in waste water, to provide a real-time alert system to warn of localised COVID-19 outbreaks. Over 60 percent of COVID-19 positive patients had gastrointestinal sym

Luina Bio is pleased to announce they have been selected to partner with XING Technologies (Brisbane) to co-develop and manufacture a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) diagnostic kit. The COVID-19 detection technology is based on a temperature-stable molecule utilising Xing patented technology. XING is looking to fast-track the development and regulatory approval of the diagnostic kit to meet customer needs in USA, Europe and the pan-Asian region. These cu

MedAlliance has announced the enrollment of the first patient in its study of SELUTION SLR ™ 014 DEB  for the treatment of intra-stent restenosis (ISR). It is the first drug eluting balloon (DEB) accepted by the FDA as part of its "capital discovery support program". SELUTION SLR ( Sustained Limus Release ) is a new sirolimus-eluting balloon that provides sustained and controlled drug release, similar to that of a drug-eluting stent (DES). The objective of this

Orchard Therapeutics, a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s principal contract development and manufacturing partners, today announced that they have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025. With the extension of the collaboration, MolMed will continue to support activities related to the development and manufacturing of vectors and drug products for several of Or

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, and Laboratorios Farmacéuticos Rovi, S.A., a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mR

Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will apply Foghorn’s proprietary Gene Traffic Control™ product platform to discover and develop novel therapeutics against a transcription factor target believed to be relevant to a broad range of

Regeneron Pharmaceuticals, Inc. announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have awarded Regeneron a $450 million contract to manufacture and supply REGN-COV2. REGN-COV2 is Re

Nephron Pharmaceuticals Corporation, one of the fastest-growing pharmaceuticals companies in the country, today announced a new collaboration with Methapharm. As a part of this collaboration, Nephron will produce kits of methacholine chloride sterile inhalation solution in ready-to-administer concentrations for bronchoprovocation challenge testing, when diagnosing respiratory illnesses, such as asthma. "Methapharm will be a fantastic partner," said Nephron CEO Lo

Dragonfly Therapeutics announces new research collaboration with Bristol Myers Squibb to develop new therapeutic candidates for multiple sclerosis and neuro-inflammation targets Dragonfly grows beyond its existing collaboration with Bristol Myers Squibb in the oncology and autoimmune disease sector to develop candidate drugs against multiple targets using its proprietary platform in new therapeutic areas WALTHAM, Massachusetts, July 6, 2020 / PRNewswire / - Dragonfly Thera

CSL Behring , world leader in biotherapeutics, announced today that the European Medicines Agency (EMA) has approved the new summary of product characteristics, which includes information on new extended dosing options for IDELVION ® [albutrepenonacog alfa, coagulation factor IX (recombinant), albumin fusion protein (rFIX-FP)], the innovative long-acting recombinant albumin fusion protein from CSL Behring for the treatment of hemophilia B 1. The regimen for routine prophylaxis has been up